GOG Foundation
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, GOG Foundation sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
GOG Foundation: 14 sponsored US clinical trials, 3 recruiting.
GOG Foundation sponsors 14 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 7 completed. 5 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Adenosquamous Carcinoma, with 2 trials.
Top-decile sponsor footprint
GOG Foundation ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
14 total, page 1 of 1
Letrozole in Uterine Leiomyosarcoma
NCT05649956
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT05154487
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
NCT01649089
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
NCT00892866
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
NCT07672782
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
NCT02228681
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
NCT01535053
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
NCT01414608
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00886691
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00888615
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01101451
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT00063999
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 6 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the GOG Foundation pipeline
3 recruiting of 14 indexed (21% open); 7 completed (50%).
Phase mix: 5 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Cervical Adenosquamous Carcinoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GOG Foundation: open-pipeline peers nationwide
Peers matched on 14 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
GOG Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 21% open enrollment (± trial volume)
- Axsome Therapeutics · 21% recruiting · 28 trials
- Kettering Health Network · 21% recruiting · 14 trials
- LifeBridge Health · 21% recruiting · 14 trials
- Olympus Corporation of the Americas · 21% recruiting · 14 trials
Related
What to do with this GOG Foundation page
14 registered trials is a research-attention snapshot, not an endorsement of GOG Foundation or any single study.
- 3 of GOG Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Adenosquamous Carcinoma is the condition GOG Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Adenosquamous Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GOG Foundation pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.